Biotech News

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update

Roivant (ROIV)RoivantEarnings

LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following

Related news

Roivant

Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2...

Recent company news

Stock data

Close
38.96 USD
Market cap
20.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States